Theravance Biopharma, Inc. Unrealized Gain (Loss) on Derivatives
Theravance Biopharma, Inc. (TBPH) reported Unrealized Gain (Loss) on Derivatives of $73.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2025-08-13
- Theravance Biopharma, Inc. unrealized gain (loss) on derivatives for the quarter ending 2025-06-30 was $35.00K.
- Theravance Biopharma, Inc. unrealized gain (loss) on derivatives for the quarter ending 2025-03-31 was $38.00K.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month |
|---|---|---|
| 2025-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $73.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $38.00K 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |